Both are hypoglycemic drugs, Dagliflozin belongs to sodium-glucose co-transporter protein 2 inhibitor, and saxagliptin belongs to dipeptidyl peptidase 4 inhibitor. 1. Sodium-glucose co-transporter protein 2 inhibitors: the principle of action is to reduce renal glucose reabsorption, lowering the renal glucose threshold, and promote glucose excretion from the urine, so as to achieve the purpose of hypoglycemia, in the lowering of glucose at the same time both lowering the cardiac preload and afterload as well as down-regulation of sympathetic nerve activity, is a new type of hypoglycemic drugs, there are daglitazide, engliflozin, and so on. 2. Dipeptidyl peptidase 4 inhibitor: the principle of action is that it can inhibit the decomposition of intestinal insulin, so as to increase the concentration of intestinal insulin, and then promote the secretion of insulin by pancreatic β-cells, so as to achieve the purpose of lowering glucose, this kind of drug is not affected by meals, and can be taken at any time of the day. These drugs are not affected by meals and can be taken at any time of the day. They are both hypoglycemic drugs but have different hypoglycemic principles. There are many kinds of hypoglycemic drugs, patients need to use them under the guidance of professional doctors to maintain blood sugar stability and avoid hypoglycemia.